-
1
-
-
84861543083
-
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
-
PMID: 22488764
-
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]
-
(2012)
Hepatology
, vol.55
, pp. 2005-2023
-
-
Chalasani, N.1
Younossi, Z.2
Lavine, J.E.3
Diehl, A.M.4
Brunt, E.M.5
Cusi, K.6
Charlton, M.7
Sanyal, A.J.8
-
2
-
-
77953971188
-
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years
-
PMID: 20581244
-
Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974 [PMID: 20581244 DOI: 10.1136/gut.2009.205088]
-
(2010)
Gut
, vol.59
, pp. 969-974
-
-
Wong, V.W.1
Wong, G.L.2
Choi, P.C.3
Chan, A.W.4
Li, M.K.5
Chan, H.Y.6
Chim, A.M.7
Yu, J.8
Sung, J.J.9
Chan, H.L.10
-
3
-
-
11144351102
-
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
-
PMID: 15629518
-
Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-138 [PMID: 15629518 DOI: 10.1016/j.jhep.2004.09.012]
-
(2005)
J Hepatol
, vol.42
, pp. 132-138
-
-
Adams, L.A.1
Sanderson, S.2
Lindor, K.D.3
Angulo, P.4
-
4
-
-
10644220306
-
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity
-
PMID: 15565570
-
Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]
-
(2004)
Hepatology
, vol.40
, pp. 1387-1395
-
-
Browning, J.D.1
Szczepaniak, L.S.2
Dobbins, R.3
Nuremberg, P.4
Horton, J.D.5
Cohen, J.C.6
Grundy, S.M.7
Hobbs, H.H.8
-
5
-
-
78650486196
-
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study
-
PMID: 20858492
-
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]
-
(2011)
Gastroenterology
, vol.140
, pp. 124-131
-
-
Williams, C.D.1
Stengel, J.2
Asike, M.I.3
Torres, D.M.4
Shaw, J.5
Contreras, M.6
Landt, C.L.7
Harrison, S.A.8
-
6
-
-
79957449923
-
Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008
-
e1; quiz e60, PMID: 21440669
-
Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530. e1; quiz e60 [PMID: 21440669 DOI: 10.1016/j.cgh.2011.03.020]
-
(2011)
Clin Gastroenterol Hepatol
, vol.9
, pp. 524-530
-
-
Younossi, Z.M.1
Stepanova, M.2
Afendy, M.3
Fang, Y.4
Younossi, Y.5
Mir, H.6
Srishord, M.7
-
7
-
-
33746421488
-
Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease
-
PMID: 16732016
-
Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006; 29: 1325-1330 [PMID: 16732016 DOI: 10.2337/dc06-0135]
-
(2006)
Diabetes Care
, vol.29
, pp. 1325-1330
-
-
Targher, G.1
Bertolini, L.2
Padovani, R.3
Rodella, S.4
Zoppini, G.5
Zenari, L.6
Cigolini, M.7
Falezza, G.8
Arcaro, G.9
-
8
-
-
50849096389
-
Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review
-
PMID: 18672311
-
Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49: 600-607 [PMID: 18672311 DOI: 10.1016/j.jhep.2008.06.012]
-
(2008)
J Hepatol
, vol.49
, pp. 600-607
-
-
Sookoian, S.1
Pirola, C.J.2
-
9
-
-
34247605492
-
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients
-
PMID: 17277038
-
Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218 [PMID: 17277038 DOI: 10.2337/dc06-2247]
-
(2007)
Diabetes Care
, vol.30
, pp. 1212-1218
-
-
Targher, G.1
Bertolini, L.2
Padovani, R.3
Rodella, S.4
Tessari, R.5
Zenari, L.6
Day, C.7
Arcaro, G.8
-
10
-
-
22344452893
-
The natural history of nonalcoholic fatty liver disease: a population-based cohort study
-
PMID: 16012941
-
Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121 [PMID: 16012941 DOI: 10.1053/j.gastro.2005.04.014]
-
(2005)
Gastroenterology
, vol.129
, pp. 113-121
-
-
Adams, L.A.1
Lymp, J.F.2
St Sauver, J.3
Sanderson, S.O.4
Lindor, K.D.5
Feldstein, A.6
Angulo, P.7
-
11
-
-
33750606061
-
Long-term follow-up of patients with NAFLD and elevated liver enzymes
-
PMID: 17006923
-
Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873 [PMID: 17006923 DOI: 10.1002/hep.21327]
-
(2006)
Hepatology
, vol.44
, pp. 865-873
-
-
Ekstedt, M.1
Franzén, L.E.2
Mathiesen, U.L.3
Thorelius, L.4
Holmqvist, M.5
Bodemar, G.6
Kechagias, S.7
-
12
-
-
34547673500
-
Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients
-
PMID: 17519430
-
Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-2121 [PMID: 17519430 DOI: 10.2337/dc07-0349]
-
(2007)
Diabetes Care
, vol.30
, pp. 2119-2121
-
-
Targher, G.1
Bertolini, L.2
Rodella, S.3
Tessari, R.4
Zenari, L.5
Lippi, G.6
Arcaro, G.7
-
13
-
-
84890737076
-
Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome
-
PMID: 24303090
-
Tziomalos K, Giampatzis V, Bouziana SD, Spanou M, Papadopoulou M, Pavlidis A, Kostaki S, Bozikas A, Savopoulos C, Hatzitolios AI. Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome. World J Hepatol 2013; 5: 621-626 [PMID: 24303090 DOI: 10.4254/wjh.v5.i11.621]
-
(2013)
World J Hepatol
, vol.5
, pp. 621-626
-
-
Tziomalos, K.1
Giampatzis, V.2
Bouziana, S.D.3
Spanou, M.4
Papadopoulou, M.5
Pavlidis, A.6
Kostaki, S.7
Bozikas, A.8
Savopoulos, C.9
Hatzitolios, A.I.10
-
14
-
-
0031947715
-
Steatohepatitis: a tale of two "hits"?
-
PMID: 9547102
-
Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102 DOI: 10.1016/S0016-5085(98)70599-2]
-
(1998)
Gastroenterology
, vol.114
, pp. 842-845
-
-
Day, C.P.1
James, O.F.2
-
15
-
-
84897449323
-
Inhibition of apoptosis in the management of nonalcoholic fatty liver disease
-
PMID: 23516172
-
Bouziana SD, Tziomalos K. Inhibition of apoptosis in the management of nonalcoholic fatty liver disease. World J Gastrointest Pharmacol Ther 2013; 4: 4-8 [PMID: 23516172 DOI: 10.4292/wjgpt.v4.i1.4]
-
(2013)
World J Gastrointest Pharmacol Ther
, vol.4
, pp. 4-8
-
-
Bouziana, S.D.1
Tziomalos, K.2
-
16
-
-
84886906559
-
Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment
-
PMID: 23355909
-
Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol 2012; 4: 327-331 [PMID: 23355909 DOI: 10.4254/wjh.v4.i12.327]
-
(2012)
World J Hepatol
, vol.4
, pp. 327-331
-
-
Paschos, P.1
Tziomalos, K.2
-
17
-
-
84857132090
-
Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options
-
PMID: 22239625
-
Tziomalos K, Athyros VG, Karagiannis A. Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol 2012; 10: 162-172 [PMID: 22239625 DOI: 10.2174/157016112799305012]
-
(2012)
Curr Vasc Pharmacol
, vol.10
, pp. 162-172
-
-
Tziomalos, K.1
Athyros, V.G.2
Karagiannis, A.3
-
18
-
-
77957375969
-
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
-
PMID: 20879883
-
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350 [PMID: 20879883 DOI: 10.1056/NEJMra0912063]
-
(2010)
N Engl J Med
, vol.363
, pp. 1341-1350
-
-
Targher, G.1
Day, C.P.2
Bonora, E.3
-
19
-
-
36549034768
-
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths
-
PMID: 18061058
-
Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829-1839 [PMID: 18061058 DOI: 10.1016/S0140-6736(07)61778-4]
-
(2007)
Lancet
, vol.370
, pp. 1829-1839
-
-
Lewington, S.1
Whitlock, G.2
Clarke, R.3
Sherliker, P.4
Emberson, J.5
Halsey, J.6
Qizilbash, N.7
Peto, R.8
Collins, R.9
-
20
-
-
78449281377
-
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
-
PMID: 21067804
-
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681 [PMID: 21067804 DOI: 10.1016/S0140-6736(10)61350-5]
-
(2010)
Lancet
, vol.376
, pp. 1670-1681
-
-
Baigent, C.1
Blackwell, L.2
Emberson, J.3
Holland, L.E.4
Reith, C.5
Bhala, N.6
Peto, R.7
Barnes, E.H.8
Keech, A.9
Simes, J.10
Collins, R.11
-
21
-
-
35748962429
-
The safety of statins in clinical practice
-
PMID: 17559928
-
Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-1790 [PMID: 17559928 DOI: 10.1016/S0140-6736(07)60716-8]
-
(2007)
Lancet
, vol.370
, pp. 1781-1790
-
-
Armitage, J.1
-
22
-
-
79960539641
-
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
-
PMID: 21712404
-
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818 [PMID: 21712404 DOI: 10.1093/eurheartj/ehr158]
-
(2011)
Eur Heart J
, vol.32
, pp. 1769-1818
-
-
Reiner, Z.1
Catapano, A.L.2
De Backer, G.3
Graham, I.4
Taskinen, M.R.5
Wiklund, O.6
Agewall, S.7
Alegria, E.8
Chapman, M.J.9
Durrington, P.10
Erdine, S.11
Halcox, J.12
Hobbs, R.13
Kjekshus, J.14
Filardi, P.P.15
Riccardi, G.16
Storey, R.F.17
Wood, D.18
-
23
-
-
78649890465
-
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
-
PMID: 21109302
-
Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-1922 [PMID: 21109302 DOI: 10.1016/S0140-6736(10)61272-X]
-
(2010)
Lancet
, vol.376
, pp. 1916-1922
-
-
Athyros, V.G.1
Tziomalos, K.2
Gossios, T.D.3
Griva, T.4
Anagnostis, P.5
Kargiotis, K.6
Pagourelias, E.D.7
Theocharidou, E.8
Karagiannis, A.9
Mikhailidis, D.P.10
-
24
-
-
84886254094
-
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-tomoderate baseline elevations in alanine aminotransferase levels
-
PMID: 24001698
-
Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, Kastelein JJ, Holme I, Pedersen TR. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-tomoderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168: 3846-3852 [PMID: 24001698 DOI: 10.1016/j.ijcard.2013.06.024]
-
(2013)
Int J Cardiol
, vol.168
, pp. 3846-3852
-
-
Tikkanen, M.J.1
Fayyad, R.2
Faergeman, O.3
Olsson, A.G.4
Wun, C.C.5
Laskey, R.6
Kastelein, J.J.7
Holme, I.8
Pedersen, T.R.9
-
25
-
-
2142768218
-
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
-
PMID: 15131789
-
Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287-1292 [PMID: 15131789 DOI: 10.1053/j.gastro.2004.02.015]
-
(2004)
Gastroenterology
, vol.126
, pp. 1287-1292
-
-
Chalasani, N.1
Aljadhey, H.2
Kesterson, J.3
Murray, M.D.4
Hall, S.D.5
-
26
-
-
0037150209
-
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project
-
PMID: 12021218
-
Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, Davis BR, Friedman CP, Braunwald E. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105: 2341-2346 [PMID: 12021218 DOI: 10.1161/01. CIR.0000017634.00171.24]
-
(2002)
Circulation
, vol.105
, pp. 2341-2346
-
-
Pfeffer, M.A.1
Keech, A.2
Sacks, F.M.3
Cobbe, S.M.4
Tonkin, A.5
Byington, R.P.6
Davis, B.R.7
Friedman, C.P.8
Braunwald, E.9
-
27
-
-
81555203011
-
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study
-
PMID: 22291824
-
Athyros VG, Giouleme O, Ganotakis ES, Elisaf M, Tziomalos K, Vassiliadis T, Liberopoulos EN, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7: 796-805 [PMID: 22291824 DOI: 10.5114/aoms.2011.25554]
-
(2011)
Arch Med Sci
, vol.7
, pp. 796-805
-
-
Athyros, V.G.1
Giouleme, O.2
Ganotakis, E.S.3
Elisaf, M.4
Tziomalos, K.5
Vassiliadis, T.6
Liberopoulos, E.N.7
Theocharidou, E.8
Karagiannis, A.9
Mikhailidis, D.P.10
-
28
-
-
0037143688
-
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
-
PMID: 12186811
-
Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106: 1024-1028 [PMID: 12186811 DOI: 10.1161/01.CIR.0000032466.44170.44]
-
(2002)
Circulation
, vol.106
, pp. 1024-1028
-
-
Pasternak, R.C.1
Smith, S.C.2
Bairey-Merz, C.N.3
Grundy, S.M.4
Cleeman, J.I.5
Lenfant, C.6
-
30
-
-
79953880237
-
Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?
-
PMID: 21476786
-
Athyros VG, Tziomalos K, Daskalopoulos GN, Karagiannis A, Mikhailidis DP. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011; 43: 167-171 [PMID: 21476786 DOI: 10.3109/07853890.2011.561363]
-
(2011)
Ann Med
, vol.43
, pp. 167-171
-
-
Athyros, V.G.1
Tziomalos, K.2
Daskalopoulos, G.N.3
Karagiannis, A.4
Mikhailidis, D.P.5
-
31
-
-
2342456307
-
Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study
-
PMID: 15135271
-
Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004; 174: 193-196 [PMID: 15135271 DOI: 10.1016/j.atherosclerosis.2004.01.008]
-
(2004)
Atherosclerosis
, vol.174
, pp. 193-196
-
-
Rallidis, L.S.1
Drakoulis, C.K.2
Parasi, A.S.3
-
32
-
-
34047271926
-
Therapeutic options in nonalcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study
-
PMID: 17410287
-
Georgescu EF, Georgescu M. Therapeutic options in nonalcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16: 39-46 [PMID: 17410287]
-
(2007)
J Gastrointestin Liver Dis
, vol.16
, pp. 39-46
-
-
Georgescu, E.F.1
Georgescu, M.2
-
33
-
-
77955664397
-
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH
-
PMID: 20112031
-
Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750-757 [PMID: 20112031 DOI: 10.1007/s00535-010-0203-y]
-
(2010)
J Gastroenterol
, vol.45
, pp. 750-757
-
-
Kimura, Y.1
Hyogo, H.2
Yamagishi, S.3
Takeuchi, M.4
Ishitobi, T.5
Nabeshima, Y.6
Arihiro, K.7
Chayama, K.8
-
34
-
-
55649083505
-
Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia
-
PMID: 19013295
-
Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, Ishitobi T, Nonaka M, Chayama K. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-1718 [PMID: 19013295 DOI: 10.1016/j.metabol.2008.07.030]
-
(2008)
Metabolism
, vol.57
, pp. 1711-1718
-
-
Hyogo, H.1
Tazuma, S.2
Arihiro, K.3
Iwamoto, K.4
Nabeshima, Y.5
Inoue, M.6
Ishitobi, T.7
Nonaka, M.8
Chayama, K.9
-
35
-
-
84910010800
-
Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report
-
PMID: 24805248
-
Kargiotis K, Katsiki N, Athyros VG, Giouleme O, Patsiaoura K, Katsiki E, Mikhailidis DP, Karagiannis A. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Curr Vasc Pharmacol 2014; 12: 505-511 [PMID: 24805248]
-
(2014)
Curr Vasc Pharmacol
, vol.12
, pp. 505-511
-
-
Kargiotis, K.1
Katsiki, N.2
Athyros, V.G.3
Giouleme, O.4
Patsiaoura, K.5
Katsiki, E.6
Mikhailidis, D.P.7
Karagiannis, A.8
-
36
-
-
74949102941
-
A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial
-
PMID: 19448566
-
Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 2009; 43: 990-994 [PMID: 19448566 DOI: 10.1097/MCG.0b013e31819c392e]
-
(2009)
J Clin Gastroenterol
, vol.43
, pp. 990-994
-
-
Nelson, A.1
Torres, D.M.2
Morgan, A.E.3
Fincke, C.4
Harrison, S.A.5
-
37
-
-
84881491358
-
Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis
-
PMID: 23063971
-
Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013; 144: 323-332 [PMID: 23063971 DOI: 10.1053/j.gastro.2012.10.005]
-
(2013)
Gastroenterology
, vol.144
, pp. 323-332
-
-
Singh, S.1
Singh, P.P.2
Singh, A.G.3
Murad, M.H.4
Sanchez, W.5
-
38
-
-
84863115964
-
Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection
-
PMID: 22271485
-
Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012; 30: 623-630 [PMID: 22271485 DOI: 10.1200/JCO.2011.36.0917]
-
(2012)
J Clin Oncol
, vol.30
, pp. 623-630
-
-
Tsan, Y.T.1
Lee, C.H.2
Wang, J.D.3
Chen, P.C.4
-
39
-
-
84876516919
-
Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection
-
PMID: 23509319
-
Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013; 31: 1514-1521 [PMID: 23509319 DOI: 10.1200/JCO.2012.44.6831]
-
(2013)
J Clin Oncol
, vol.31
, pp. 1514-1521
-
-
Tsan, Y.T.1
Lee, C.H.2
Ho, W.C.3
Lin, M.H.4
Wang, J.D.5
Chen, P.C.6
-
40
-
-
34548125027
-
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy
-
PMID: 17659159
-
Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-2026 [PMID: 17659159 DOI: 10.1185/030079907X210507]
-
(2007)
Curr Med Res Opin
, vol.23
, pp. 2009-2026
-
-
Mikhailidis, D.P.1
Sibbring, G.C.2
Ballantyne, C.M.3
Davies, G.M.4
Catapano, A.L.5
-
41
-
-
77955519012
-
NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease
-
PMID: 20222991
-
Enjoji M, Machida K, Kohjima M, Kato M, Kotoh K, Matsunaga K, Nakashima M, Nakamuta M. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis 2010; 9: 29 [PMID: 20222991 DOI: 10.1186/1476-511X-9-29]
-
(2010)
Lipids Health Dis
, vol.9
, pp. 29
-
-
Enjoji, M.1
Machida, K.2
Kohjima, M.3
Kato, M.4
Kotoh, K.5
Matsunaga, K.6
Nakashima, M.7
Nakamuta, M.8
-
42
-
-
77954366025
-
Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study
-
PMID: 20412324
-
Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Kubota K, Maeyama S, Nakajima A. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol Res 2010; 40: 566-573 [PMID: 20412324 DOI: 10.1111/j.1872-034X.2010.00644.x]
-
(2010)
Hepatol Res
, vol.40
, pp. 566-573
-
-
Yoneda, M.1
Fujita, K.2
Nozaki, Y.3
Endo, H.4
Takahashi, H.5
Hosono, K.6
Suzuki, K.7
Mawatari, H.8
Kirikoshi, H.9
Inamori, M.10
Saito, S.11
Iwasaki, T.12
Terauchi, Y.13
Kubota, K.14
Maeyama, S.15
Nakajima, A.16
-
43
-
-
78651473467
-
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease
-
PMID: 20658156
-
Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, Nakamura N, Ohta M, Obayashi H, Okanoue T. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-107 [PMID: 20658156 DOI: 10.1007/s00535-010-0291-8]
-
(2011)
J Gastroenterol
, vol.46
, pp. 101-107
-
-
Park, H.1
Shima, T.2
Yamaguchi, K.3
Mitsuyoshi, H.4
Minami, M.5
Yasui, K.6
Itoh, Y.7
Yoshikawa, T.8
Fukui, M.9
Hasegawa, G.10
Nakamura, N.11
Ohta, M.12
Obayashi, H.13
Okanoue, T.14
-
44
-
-
84898600580
-
The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial
-
PMID: 24407920
-
Takeshita Y, Takamura T, Honda M, Kita Y, Zen Y, Kato K, Misu H, Ota T, Nakamura M, Yamada K, Sunagozaka H, Arai K, Yamashita T, Mizukoshi E, Kaneko S. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014; 57: 878-890 [PMID: 24407920 DOI: 10.1007/s00125-013-3149-9]
-
(2014)
Diabetologia
, vol.57
, pp. 878-890
-
-
Takeshita, Y.1
Takamura, T.2
Honda, M.3
Kita, Y.4
Zen, Y.5
Kato, K.6
Misu, H.7
Ota, T.8
Nakamura, M.9
Yamada, K.10
Sunagozaka, H.11
Arai, K.12
Yamashita, T.13
Mizukoshi, E.14
Kaneko, S.15
-
45
-
-
84878626719
-
Colesevelam: a new and improved bile acid sequestrant?
-
PMID: 23317402
-
Tziomalos K, Karagiannis A, Mikhailidis DP, Athyros VG. Colesevelam: a new and improved bile acid sequestrant? Curr Pharm Des 2013; 19: 3115-3123 [PMID: 23317402 DOI: 10.2174/1381612811319170019]
-
(2013)
Curr Pharm Des
, vol.19
, pp. 3115-3123
-
-
Tziomalos, K.1
Karagiannis, A.2
Mikhailidis, D.P.3
Athyros, V.G.4
-
46
-
-
84865569519
-
Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial
-
PMID: 22431131
-
Le TA, Chen J, Changchien C, Peterson MR, Kono Y, Patton H, Cohen BL, Brenner D, Sirlin C, Loomba R. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012; 56: 922-932 [PMID: 22431131 DOI: 10.1002/hep.25731]
-
(2012)
Hepatology
, vol.56
, pp. 922-932
-
-
Le, T.A.1
Chen, J.2
Changchien, C.3
Peterson, M.R.4
Kono, Y.5
Patton, H.6
Cohen, B.L.7
Brenner, D.8
Sirlin, C.9
Loomba, R.10
-
47
-
-
46449124024
-
Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol
-
PMID: 18049900
-
Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M, Malekzadeh R. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci 2008; 53: 2246-2250 [PMID: 18049900 DOI: 10.1007/s10620-007-0109-6]
-
(2008)
Dig Dis Sci
, vol.53
, pp. 2246-2250
-
-
Merat, S.1
Aduli, M.2
Kazemi, R.3
Sotoudeh, M.4
Sedighi, N.5
Sohrabi, M.6
Malekzadeh, R.7
-
48
-
-
84898597579
-
Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study
-
Apr 17, Epub ahead of print, PMID: 23607264
-
Ishitobi T, Hyogo H, Tokumo H, Arihiro K, Chayama K. Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study. Hepatol Res 2013 Apr 17; Epub ahead of print [PMID: 23607264 DOI: 10.1111/hepr.12135]
-
(2013)
Hepatol Res
-
-
Ishitobi, T.1
Hyogo, H.2
Tokumo, H.3
Arihiro, K.4
Chayama, K.5
-
49
-
-
0021350001
-
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
-
PMID: 6361299
-
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364 [PMID: 6361299 DOI: 10.1001/jama.1984.03340270029025]
-
(1984)
JAMA
, vol.251
, pp. 351-364
-
-
-
50
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
PMID: 20228404
-
Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574 [PMID: 20228404 DOI: 10.1056/NEJMoa1001282]
-
(2010)
N Engl J Med
, vol.362
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
Crouse, J.R.4
Leiter, L.A.5
Linz, P.6
Friedewald, W.T.7
Buse, J.B.8
Gerstein, H.C.9
Probstfield, J.10
Grimm, R.H.11
Ismail-Beigi, F.12
Bigger, J.T.13
Goff, D.C.14
Cushman, W.C.15
Simons-Morton, D.G.16
Byington, R.P.17
-
51
-
-
77954519409
-
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease
-
PMID: 20371660
-
Fabbrini E, Mohammed BS, Korenblat KM, Magkos F, McCrea J, Patterson BW, Klein S. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010; 95: 2727-2735 [PMID: 20371660 DOI: 10.1210/jc.2009-2622]
-
(2010)
J Clin Endocrinol Metab
, vol.95
, pp. 2727-2735
-
-
Fabbrini, E.1
Mohammed, B.S.2
Korenblat, K.M.3
Magkos, F.4
McCrea, J.5
Patterson, B.W.6
Klein, S.7
-
52
-
-
33745046866
-
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
-
PMID: 16709309
-
Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-883 [PMID: 16709309 DOI: 10.1185/030079906X104696]
-
(2006)
Curr Med Res Opin
, vol.22
, pp. 873-883
-
-
Athyros, V.G.1
Mikhailidis, D.P.2
Didangelos, T.P.3
Giouleme, O.I.4
Liberopoulos, E.N.5
Karagiannis, A.6
Kakafika, A.I.7
Tziomalos, K.8
Burroughs, A.K.9
Elisaf, M.S.10
-
53
-
-
38749085998
-
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
-
PMID: 18261709
-
Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008; 40: 200-205 [PMID: 18261709 DOI: 10.1016/j.dld.2007.10.002]
-
(2008)
Dig Liver Dis
, vol.40
, pp. 200-205
-
-
Fernández-Miranda, C.1
Pérez-Carreras, M.2
Colina, F.3
López-Alonso, G.4
Vargas, C.5
Solís-Herruzo, J.A.6
-
54
-
-
33947583493
-
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis
-
PMID: 17398308
-
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis. Lancet 2007; 369: 1090-1098 [PMID: 17398308 DOI: 10.1016/S0140-6736(07)60527-3]
-
(2007)
Lancet
, vol.369
, pp. 1090-1098
-
-
Yokoyama, M.1
Origasa, H.2
Matsuzaki, M.3
Matsuzawa, Y.4
Saito, Y.5
Ishikawa, Y.6
Oikawa, S.7
Sasaki, J.8
Hishida, H.9
Itakura, H.10
Kita, T.11
Kitabatake, A.12
Nakaya, N.13
Sakata, T.14
Shimada, K.15
Shirato, K.16
-
55
-
-
4344593276
-
Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia
-
PMID: 15333967
-
Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, Karagiannopoulou G, Tzioufa V, Dimitrios K. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23: 131-134 [PMID: 15333967]
-
(2004)
Indian J Gastroenterol
, vol.23
, pp. 131-134
-
-
Hatzitolios, A.1
Savopoulos, C.2
Lazaraki, G.3
Sidiropoulos, I.4
Haritanti, P.5
Lefkopoulos, A.6
Karagiannopoulou, G.7
Tzioufa, V.8
Dimitrios, K.9
-
56
-
-
33646882162
-
Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study
-
PMID: 16611275
-
Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, Svegliati-Baroni G, Sofi F, Milani S, Abbate R, Surrenti C, Casini A. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23: 1143-1151 [PMID: 16611275 DOI: 10.1111/j.1365-2036.2006.02885.x]
-
(2006)
Aliment Pharmacol Ther
, vol.23
, pp. 1143-1151
-
-
Capanni, M.1
Calella, F.2
Biagini, M.R.3
Genise, S.4
Raimondi, L.5
Bedogni, G.6
Svegliati-Baroni, G.7
Sofi, F.8
Milani, S.9
Abbate, R.10
Surrenti, C.11
Casini, A.12
-
57
-
-
38749115791
-
Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease
-
PMID: 18054848
-
Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, Papa G, Rabuazzo AM, Purrello F. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008; 40: 194-199 [PMID: 18054848 DOI: 10.1016/j.dld.2007.10.003]
-
(2008)
Dig Liver Dis
, vol.40
, pp. 194-199
-
-
Spadaro, L.1
Magliocco, O.2
Spampinato, D.3
Piro, S.4
Oliveri, C.5
Alagona, C.6
Papa, G.7
Rabuazzo, A.M.8
Purrello, F.9
-
58
-
-
63449137594
-
Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia
-
PMID: 19009658
-
Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008; 14: 6395-6400 [PMID: 19009658 DOI: 10.3748/wjg.14.6395]
-
(2008)
World J Gastroenterol
, vol.14
, pp. 6395-6400
-
-
Zhu, F.S.1
Liu, S.2
Chen, X.M.3
Huang, Z.G.4
Zhang, D.W.5
-
59
-
-
41349102802
-
Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis
-
PMID: 18277895
-
Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42: 413-418 [PMID: 18277895 DOI: 10.1097/MCG.0b013e31815591aa]
-
(2008)
J Clin Gastroenterol
, vol.42
, pp. 413-418
-
-
Tanaka, N.1
Sano, K.2
Horiuchi, A.3
Tanaka, E.4
Kiyosawa, K.5
Aoyama, T.6
-
60
-
-
84855171302
-
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
-
PMID: 22085343
-
Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-2267 [PMID: 22085343 DOI: 10.1056/NEJMoa1107579]
-
(2011)
N Engl J Med
, vol.365
, pp. 2255-2267
-
-
Boden, W.E.1
Probstfield, J.L.2
Anderson, T.3
Chaitman, B.R.4
Desvignes-Nickens, P.5
Koprowicz, K.6
McBride, R.7
Teo, K.8
Weintraub, W.9
-
61
-
-
84877299845
-
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
-
PMID: 23444397
-
HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-1291 [PMID: 23444397 DOI: 10.1093/eurheartj/eht055]
-
(2013)
Eur Heart J
, vol.34
, pp. 1279-1291
-
-
-
62
-
-
84910016169
-
Niacin causes serious unexpected sideeffects, but no worthwhile benefits, for patients who are at increased risk of heart attacks and strokes
-
updated 2013 March 9; cited, May 17, Available from: URL
-
HPS2-THRIVE. Niacin causes serious unexpected sideeffects, but no worthwhile benefits, for patients who are at increased risk of heart attacks and strokes (updated 2013 March 9; cited 2014 May 17). Available from: URL: http://www.thrivestudy.org/press_release.htm
-
(2014)
-
-
|